Silencing CCT3 inhibits the proliferation and viability of tumor cells in breast cancer, lung cancer, liver cancer, melanoma, cervical cancer, and prostate cancer, leading to cell cycle arrest.[19,20,27,34,35] Depletion of the CCT induces cell cycle arrest during mitosis and increases the percentage of abnormal mitotic cells. Here, FLVCR2 is linked to breast cancer.